EndoQuest Robotics Secures $42M in C-1 Financing

EndoQuest Robotics, a developer of innovative endoluminal robotic technologies, announced the successful closure of a $42 million C-1 preferred financing round. The financing will help fund advancements to the company’s flexible endoluminal robot which is meant to address unmet needs in gastrointestinal and other endoluminal surgeries.

The robot, according to the company, offers precision, flexibility, and improved patient outcomes by navigating and performing procedures within the body’s luminal spaces, allowing for minimally invasive interventions and enhanced clinician capabilities.

Led by EndoQuest legacy investors, CE Ventures Limited and McNair Interests, the company also saw funding from Puma Venture Capital as a new investor. The newly acquired capital will allow the company to drive key initiatives, including further R&D, regulatory milestones, and commercialization efforts, along with strengthening its position in the flexible endoluminal robotics market.

"Our investors share our vision of leveraging robotics to redefine the possibilities in minimally invasive procedures," said Kurt Azarbarzin, CEO of EndoQuest, in the press release. "This financing enables us to continue innovating and refining our technology, ultimately improving patient care and transforming the future of endoluminal interventions."

EndoQuests Flexible Robotic System is in development, has not been cleared by FDA, and is not for commercial sale in the United States.